AnaptysBio Inc [ANAB] stock is trading at $34.65, up 3.96%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The ANAB shares have gain 9.86% over the last week, with a monthly amount glided 0.49%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
AnaptysBio Inc [NASDAQ: ANAB] stock has seen the most recent analyst activity on July 22, 2024, when H.C. Wainwright initiated its Buy rating and assigned the stock a price target of $55. Previously, JP Morgan upgraded its rating to Overweight on July 19, 2024, and elevated its price target to $69. On April 16, 2024, Leerink Partners initiated with a Outperform rating and assigned a price target of $47 on the stock. Wells Fargo started tracking the stock assigning a Overweight rating and suggested a price target of $56 on April 11, 2024. Wedbush upgraded its rating to a Outperform and raised its price target to $34 on March 12, 2024. BTIG Research started tracking with a Buy rating for this stock on February 26, 2024, and assigned it a price target of $55. In a note dated February 21, 2024, Stifel initiated an Buy rating and provided a target price of $50 on this stock.
AnaptysBio Inc [ANAB] stock has fluctuated between $13.36 and $38.85 over the past year. Currently, Wall Street analysts expect the stock to reach $39.5 within the next 12 months. AnaptysBio Inc [NASDAQ: ANAB] shares were valued at $34.65 at the most recent close of the market. An investor can expect a potential return of 14.0% based on the average ANAB price forecast.
Analyzing the ANAB fundamentals
AnaptysBio Inc [NASDAQ:ANAB] reported sales of 30.47M for the trailing twelve months, which represents a growth of 217.08%. Gross Profit Margin for this corporation currently stands at 0.92% with Operating Profit Margin at -5.33%, Pretax Profit Margin comes in at -5.58%, and Net Profit Margin reading is -5.58%. To continue investigating profitability, this company’s Return on Assets is posted at -0.4, Equity is -2.56 and Total Capital is -0.42. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 36.83.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 32.37 points at the first support level, and at 30.08 for the second support level. However, for the 1st resistance point, the stock is sitting at 39.12, and for the 2nd resistance point, it is at 43.59.
Ratios To Look Out For
For context, AnaptysBio Inc’s Current Ratio is 9.09. As well, the Quick Ratio is 9.09, while the Cash Ratio is 1.78. Considering the valuation of this stock, the price to sales ratio is 31.22, the price to book ratio is 96.22.
Transactions by insiders
Recent insider trading involved PAUL F LIZZUL, Officer, that happened on Aug 14 ’24 when 2000.0 shares were purchased. Chief Medical Officer, Lizzul Paul F. completed a deal on Jul 18 ’24 to sell 1500.0 shares. Meanwhile, Director RENTON HOLLINGS sold 10000.0 shares on Jul 15 ’24.
